Royalty Pharma PLC

RPRX remains in a Stage 2 advancing uptrend confirmed by rising EMAs and higher highs/lows. A recent momentum breakout above prior resistance shows strong demand, but price is extended well above EMAs and tagged extreme overbought. Short-term conditions are unfavorable for fresh entries, so execution should be deferred until a pullback into the rising EMA and former resistance zone shows clear acceptance.

• ↑Portfolio receipts rose 20% YoY to $727M; royalty receipts up 11% to $672M
• ↑Full-year 2025 guidance increased to $3.05–$3.15B, implying 9–12% growth
• ↓Milestone and contract revenues declining from $128M in ’25 to ~$60M in ’26